Roche drug succeeds in hard-to-treat form of multiple sclerosis

Reuters: Switzerland's Roche has a potential new multi-billion-dollar drug to help it diversify beyond cancer treatments following the success of ocrelizumab against a hard-to-treat type of multiple sclerosis.

Read article

i360Gov Newsletters

The most significant government policy, business, and technology news and analysis delivered to your inbox.

Subscribe Now

Trending